631 results on '"Bertrand A"'
Search Results
2. MP07-08 A FULLY AUTOMATED MULTI-TASK MACHINE LEARNING PROGNOSTIC MODEL INTEGRATING RADIOMICS AND CLINICAL DATA TO PREDICT OUTCOMES IN HIGH-GRADE PROSTATE CANCER
3. MP07-07 RADIOMICS-BASED PROGNOSTIC MODEL GUIDED BY ARTIFICIAL INTELLIGENCE FOR PREDICTING CLINICAL OUTCOMES IN INDIVIDUALS WITH HIGH-GRADE PROSTATE CANCER
4. MP14-09 DEVELOPMENT OF A PREDICTION MODEL OF SURVIVAL AMONGST PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC) USING BIG DATA: INTERIM RESULTS FROM THE EUROPEAN NETWORK OF EXCELLENCE FOR BIG DATA IN PROSTATE CANCER (PIONEER)
5. PD01-07 NATURAL HISTORY OF PN1 PROSTATE CANCER AFTER RADICAL PROSTATECTOMY: COMPETING RISK ANALYSIS FROM A LARGE MULTI-INSTITUTIONAL SERIES
6. MP29-01 RAPID, DURABLE, AND DEEP PROSTATE-SPECIFIC ANTIGEN RESPONSE FOLLOWING ADDITION OF DAROLUTAMIDE TO ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN ARASENS
7. MP29-02 EFFICACY AND SAFETY OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE NORTH AMERICAN POPULATION FROM ARASENS
8. MP29-01 RAPID, DURABLE, AND DEEP PROSTATE-SPECIFIC ANTIGEN RESPONSE FOLLOWING ADDITION OF DAROLUTAMIDE TO ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN ARASENS
9. MP29-02 EFFICACY AND SAFETY OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE NORTH AMERICAN POPULATION FROM ARASENS
10. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level
11. LBA01-07 OVERALL SAFETY AND INCIDENCES OF ADVERSE EVENTS BY TIME INTERVAL WITH DAROLUTAMIDE PLUS ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE PHASE 3 ARASENS TRIAL
12. MP27-16 ORAL RELUGOLIX FOR ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER: DETAILED SAFETY ANALYSIS FROM THE RANDOMIZED PHASE 3 HERO STUDY
13. PD35-08 ORAL RELUGOLIX FOR ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER: POOLED SAFETY ANALYSES FROM RANDOMIZED CONTROLLED STUDIES
14. MP27-16 ORAL RELUGOLIX FOR ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER: DETAILED SAFETY ANALYSIS FROM THE RANDOMIZED PHASE 3 HERO STUDY
15. PD35-08 ORAL RELUGOLIX FOR ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER: POOLED SAFETY ANALYSES FROM RANDOMIZED CONTROLLED STUDIES
16. LBA01-07 OVERALL SAFETY AND INCIDENCES OF ADVERSE EVENTS BY TIME INTERVAL WITH DAROLUTAMIDE PLUS ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE PHASE 3 ARASENS TRIAL
17. PD04-04 TRANSCORPORAL VS. BULBAR ARTIFICIAL URINARY SPHINCTER IMPLANTATION IN MALE PATIENTS WITH FRAGILE URETHRA
18. PD58-09 SURGICAL EXPERIENCE AND ONCOLOGIC QUALITY IN ROBOTIC ASSISTED LAPAROSCOPIC PROSTATECTOMY: ARE THEY ALWAYS LINKED?
19. PD04-02 PREVALENCE AND RISK FACTORS OF ARTIFICIAL URINARY SPHINCTER REVISION IN NON-NEUROLOGICAL MALE PATIENTS
20. MP24-07 RELUGOLIX VS LEUPROLIDE EFFECTS ON CASTRATION RESISTANCE-FREE SURVIVAL FROM THE PHASE 3 HERO STUDY IN MEN WITH ADVANCED PROSTATE CANCER
21. Reply by Authors
22. Prevalence and Risk Factors of Artificial Urinary Sphincter Revision in Nonneurological Male Patients
23. MP24-07 RELUGOLIX VS LEUPROLIDE EFFECTS ON CASTRATION RESISTANCE-FREE SURVIVAL FROM THE PHASE 3 HERO STUDY IN MEN WITH ADVANCED PROSTATE CANCER
24. PD04-04 TRANSCORPORAL VS. BULBAR ARTIFICIAL URINARY SPHINCTER IMPLANTATION IN MALE PATIENTS WITH FRAGILE URETHRA
25. PD58-09 SURGICAL EXPERIENCE AND ONCOLOGIC QUALITY IN ROBOTIC ASSISTED LAPAROSCOPIC PROSTATECTOMY: ARE THEY ALWAYS LINKED?
26. PD66-10 IMPACT OF THE CENTER VOLUME ACTIVITY ON THE RESULTS OF ARTIFICIAL URINARY SPHINCTER IN NON-NEUROLOGICAL MALE PATIENTS
27. PD04-02 PREVALENCE AND RISK FACTORS OF ARTIFICIAL URINARY SPHINCTER REVISION IN NON-NEUROLOGICAL MALE PATIENTS
28. LBA02-07 HERO PHASE 3 TRIAL: RESULTS COMPARING RELUGOLIX, AN ORAL GNRH RECEPTOR ANTAGONIST, VS LEUPROLIDE ACETATE FOR ADVANCED PROSTATE CANCER
29. MP20-09 SHOULD BIOPSY-NAIVE PATIENTS BE OFFERED UP-FRONT MULTI-PARAMETRIC MRI (MPMRI) SCAN AND TRANS-PERINEAL MRI-FUSION TARGETED AND SATURATION BIOPSIES?
30. PD16-08 EFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A PRE-PLANNED EQ-5D-5L ANALYSIS OF THE CARD STUDY
31. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies
32. Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo
33. Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy
34. PD16-08 EFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A PRE-PLANNED EQ-5D-5L ANALYSIS OF THE CARD STUDY
35. LBA02-07 HERO PHASE 3 TRIAL: RESULTS COMPARING RELUGOLIX, AN ORAL GNRH RECEPTOR ANTAGONIST, VS LEUPROLIDE ACETATE FOR ADVANCED PROSTATE CANCER
36. MP20-09 SHOULD BIOPSY-NAIVE PATIENTS BE OFFERED UP-FRONT MULTI-PARAMETRIC MRI (MPMRI) SCAN AND TRANS-PERINEAL MRI-FUSION TARGETED AND SATURATION BIOPSIES?
37. PD45-10 IMPACT OF CLINICAL TUMOR STAGE AND PREOPERATIVE PSA-VALUE ON CANCER SPECIFIC SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH GLEASON 9-10 ON PROSTATE BIOPSY
38. MP09-10 MULTI-INSTITUTIONAL PROSPECTIVE STUDY ASSESSING THE UNFAVORABLE SUBGROUP AMONG INTERMEDIATE-RISK LOCALIZED PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: IMPLICATIONS FOR PERSONALIZING TREATMENT OF RADICAL PROSTATECTOMY-MANAGED PATIENTS
39. Prosbiotate: A Multicenter, Prospective Analysis of Infectious Complications after Prostate Biopsy
40. Measuring and Predicting Patient Dissatisfaction after Anterior Urethroplasty Using Patient Reported Outcomes Measures
41. MP03-02 UNVEILING THE LONG-TERM SURVIVAL OUTCOMES OF ARTIFICIAL URINARY SPHINCTER: A TWELVE-YEAR STUDY FROM THE FRENCH NATIONAL HEALTH INSURANCE DATABASE.
42. MP16-18 VALIDATION OF STAMPEDE CRITERIA FOR NON-METASTATIC PROSTATE CANCER - AN EMPACT STUDY
43. MP21-15 WHEN CAN BIOCHEMICAL RECURRENCE BE CONSIDERED A SURROGATE FOR HARDER CLINICAL ENDPOINTS IN HIGH RISK PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY? RESULTS FROM A LARGE, MULTI-INSTITUTIONAL, LONG-TERM ANALYSES
44. MP52-19 IMPACT OF ENZALUTAMIDE ON PAIN AND HEALTH-RELATED QUALITY OF LIFE IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: PROSPER STUDY RESULTS
45. MP62-03 EJACULATION-PRESERVING GREENLIGHT PHOTOVAPORIZATION: SHORT- AND LONG TERM RESULTS
46. PD42-12 ONCOLOGICAL OUTCOMES OF UNFAVORABLE INTERMEDIATE-RISK IS COMPARABLE TO HIGH-RISK LOCALIZED PROSTATE CANCER IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION
47. MP59-01 IMPACT OF HOSPITAL VOLUME AND SURGEON VOLUME ON ROBOT-ASSISTED PARTIAL NEPHRECTOMY OUTCOMES: A MULTICENTER STUDY
48. MP24-08 REFINING THE RISK-STRATIFICATION OF TRANSRECTAL-BIOPSY DETECTED PROSTATE CANCER BY ELASTIC FUSION REGISTRATION TRANSPERINEAL BIOPSIES
49. MP09-10 MULTI-INSTITUTIONAL PROSPECTIVE STUDY ASSESSING THE UNFAVORABLE SUBGROUP AMONG INTERMEDIATE-RISK LOCALIZED PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: IMPLICATIONS FOR PERSONALIZING TREATMENT OF RADICAL PROSTATECTOMY-MANAGED PATIENTS
50. MP42-10 LONG TERM TRIFECTA OUTCOMES OF PARTIAL NEPHRECTOMY VERSUS PERCUTANEOUS ABLATION IN CT1A RENAL MASSES
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.